Treatment of Strongyloides Infection

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the serologic response in patients with S. stercoralis infection after treatment with a regimen of two single doses of 200 µg/kg of ivermectin given 2 weeks apart versus a regimen of two single doses of 200 µg/kg of ivermectin given in two consecutive days.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Einstein College of Medicine; Albert Einstein College of Medicine, Inc.
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• At least 18 years of age

• Positive for Strongyloides serology infection (as determined by ELISA)

Exclusion Criteria:

• Severe intestinal Strongyloides infection

• Disseminated Strongyloidiasis infection

• Pregnant and breastfeeding women

• HTLV-1 co-infection

• Patients with indeterminate results on Strongyloides serology

• Patients who are immunosuppressed

• Unable to read and understand consent form